GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharnext SA (XPAR:ALPHA) » Definitions » Total Current Liabilities

Pharnext (XPAR:ALPHA) Total Current Liabilities : €9.50 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Pharnext Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Pharnext's total current liabilities for the quarter that ended in Dec. 2023 was €9.50


Pharnext Total Current Liabilities Historical Data

The historical data trend for Pharnext's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharnext Total Current Liabilities Chart

Pharnext Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.96 15.52 19.31 8.18 9.50

Pharnext Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.31 24.36 8.18 10.87 9.50

Pharnext Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Pharnext's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=9.229+0.001
+Other Current Liabilities+Current Deferred Liabilities
=0.272+0
=9.50

Pharnext's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=9.229+0.001
+Other Current Liabilities+Current Deferred Liabilities
=0.272+0
=9.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Pharnext Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Pharnext's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharnext (XPAR:ALPHA) Business Description

Traded in Other Exchanges
Address
11-13 Rue Rene Jacques, Issy-Les-Moulineaux, FRA, 92130
Pharnext SA is a biopharmaceutical company developing treatments targeting neurodegenerative diseases. The company also develop a Pleotherapy technology platform. Its product in the pipeline includes SYNGILITY; PXT3003 and PXT864. The company's only segment being research and development on new pharmaceutical therapies based on Pleotherapy.

Pharnext (XPAR:ALPHA) Headlines

No Headlines